Lumos Pharma, Inc. (LUMO): Price and Financial Metrics
GET POWR RATINGS... FREE!
LUMO Stock Summary
- For LUMO, its debt to operating expenses ratio is greater than that reported by just 5.51% of US equities we're observing.
- With a year-over-year growth in debt of -50.86%, LUMOS PHARMA INC's debt growth rate surpasses just 5.35% of about US stocks.
- Revenue growth over the past 12 months for LUMOS PHARMA INC comes in at 2,362%, a number that bests 99.6% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to LUMOS PHARMA INC, a group of peers worth examining would be RYTM, BYSI, ALBO, PTN, and HCWB.
- LUMO's SEC filings can be seen here. And to visit LUMOS PHARMA INC's official web site, go to www.lumos-pharma.com.
LUMO Valuation Summary
- In comparison to the median Healthcare stock, LUMO's EV/EBIT ratio is 85.22% lower, now standing at 1.5.
- Over the past 137 months, LUMO's price/sales ratio has gone down 26.
Below are key valuation metrics over time for LUMO.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| LUMO | 2023-01-30 | 24.1 | 0.4 | -1.0 | 1.5 |
| LUMO | 2023-01-27 | 23.5 | 0.4 | -1.0 | 1.5 |
| LUMO | 2023-01-26 | 24.3 | 0.4 | -1.1 | 1.5 |
| LUMO | 2023-01-25 | 24.4 | 0.4 | -1.1 | 1.5 |
| LUMO | 2023-01-24 | 24.5 | 0.4 | -1.1 | 1.5 |
| LUMO | 2023-01-23 | 23.4 | 0.4 | -1.0 | 1.5 |
LUMO Growth Metrics
- Its year over year revenue growth rate is now at 131.97%.
- Its 2 year cash and equivalents growth rate is now at 1.09%.
- Its 4 year net cashflow from operations growth rate is now at 56.26%.
The table below shows LUMO's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 1.231 | -26.625 | -28.456 |
| 2022-06-30 | 0.734 | -28.145 | -28.693 |
| 2022-03-31 | 0.341 | -27.269 | -29.519 |
| 2021-12-31 | 0.23 | -29.648 | -30.43 |
| 2021-09-30 | 0.05 | -30.8 | -27.204 |
| 2021-06-30 | 0.124 | -23.368 | -17.951 |
LUMO's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- LUMO has a Quality Grade of D, ranking ahead of 21.86% of graded US stocks.
- LUMO's asset turnover comes in at 0.001 -- ranking 434th of 681 Pharmaceutical Products stocks.
- INVA, RETA, and SUPN are the stocks whose asset turnover ratios are most correlated with LUMO.
The table below shows LUMO's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.001 | 1 | -1.992 |
| 2021-03-31 | 0.001 | 1 | -0.861 |
| 2020-12-31 | 0.001 | 1 | -0.498 |
| 2020-09-30 | 0.004 | 1 | -0.644 |
| 2020-06-30 | 0.005 | 1 | -1.373 |
| 2020-03-31 | 0.007 | 1 | -2.610 |
LUMO Price Target
For more insight on analysts targets of LUMO, see our LUMO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $27.00 | Average Broker Recommendation | 1.42 (Moderate Buy) |
LUMO Stock Price Chart Interactive Chart >
LUMO Price/Volume Stats
| Current price | $3.53 | 52-week high | $10.27 |
| Prev. close | $3.40 | 52-week low | $2.95 |
| Day low | $3.48 | Volume | 18,601 |
| Day high | $3.61 | Avg. volume | 17,681 |
| 50-day MA | $3.81 | Dividend yield | N/A |
| 200-day MA | $7.01 | Market Cap | 29.64M |
Lumos Pharma, Inc. (LUMO) Company Bio
Lumos Pharma, Inc. operates as a biopharmaceutical company. The Company discovers, develops, and commercializes therapeutics for patients and families living with rare diseases. Lumos Pharma operates worldwide.
Latest LUMO News From Around the Web
Below are the latest news stories about LUMOS PHARMA INC that investors may wish to consider to help them evaluate LUMO as an investment opportunity.
Lumos Pharma to Participate in 12th Annual LifeSci Partners Corporate Access Event January 9-11, 202312th Annual Corporate Access Event Register for in-person meetings with Lumos Pharma AUSTIN, Texas, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced that the Company will participate in the 12th Annual LifeSci Partners Corporate Access Event held in San Francisco January 9-11, 2023. Lumos Pharma will host in-person one-on |
KOL Review of Lumos Pharma’s Interim Phase 2 Data Supports Potential for New Oral Therapeutic Paradigm for Moderate Idiopathic PGHD PatientsAUSTIN, Texas, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on rare disorders, hosted two key opinion leaders (KOLs) in the field of pediatric endocrinology on December 6th to review the Company’s interim data from two Phase 2 trials evaluating oral LUM-201 in moderate idiopathic Pediatric Growth Hormone Deficiency (iPGHD). Andrew Dauber, MD, MMSc, Chief of Endocrinology, Children’s National Hospital, and Fernando Cassorla |
Lumos Pharma to Host KOL Webinar to Discuss Interim Phase 2 Data from OraGrowtH Trials in PGHDAUSTIN, Texas, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on rare endocrine disorders, announced that the Company will host two key opinion leaders in the field of pediatric endocrinology for a discussion of interim data from our Phase 2 OraGrowtH210 and PK/PD OraGrowtH212 Trials evaluating oral LUM-201 in Pediatric Growth Hormone Deficiency (PGHD). The KOL webinar will take place on December 6th at 2:00 PM EST. Event:KO |
Lumos Pharma to Participate in the Piper Sandler 34th Annual Healthcare ConferenceAUSTIN, Texas, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials for Pediatric Growth Hormone Deficiency (PGHD), announced that the Company will present and host one-on-one meetings at the Piper Sandler 34th Annual Healthcare Conference November 29th through December 1st. Event: Piper Sandler 34th Annual Healthcare Conference – November 29th – December 1stPresentat |
Lumos Pharma, Inc. 2022 Q3 - Results - Earnings Call Presentation (NASDAQ:LUMO)The following slide deck was published by Lumos Pharma, Inc. |
LUMO Price Returns
| 1-mo | -11.31% |
| 3-mo | -60.91% |
| 6-mo | -59.31% |
| 1-year | -64.05% |
| 3-year | -76.37% |
| 5-year | -94.24% |
| YTD | -2.22% |
| 2022 | -47.91% |
| 2021 | -80.59% |
| 2020 | 56.83% |
| 2019 | 66.45% |
| 2018 | -81.26% |
Loading social stream, please wait...